Pelthos Therapeutics Posts 17% Revenue Growth, Secures $50M Loan Despite $10.2M Loss
PTHS•Pelthos Therapeutics reported 17% QoQ revenue growth in Q1 2026 driven by a 25% rise in ZelSUDME prescriptions and sales force rose from 50 to 64 reps. It secured a $50 million term loan but posted a $10.2 million net loss, 14% higher SG&A and $2.4 million in interest expenses.
1. Revenue Growth and Sales Force Expansion
Pelthos posted a 17% quarter-over-quarter net revenue increase for Q1 2026, supported by expanding its field team from 50 to 64 territory reps to broaden its U.S. market presence.
2. ZelSUDME Prescription Uptake and Coverage
ZelSUDME prescriptions climbed 25% quarter over quarter, and coverage stands at 59% under commercial plans and 99% under Medicaid, underscoring strong adoption in dermatology and growing use among pediatricians.
3. Financial Position and Expenses
The company bolstered liquidity with a $50 million term debt facility but recorded a $10.2 million net loss, with COGS at $1.7 million, SG&A expenses up 14%, and interest charges rising to $2.4 million in the quarter.
4. Strategy and Future Outlook
Management indicated repeat prescriber rates are rising and anticipates growth-to-net margins improving to the mid-30% range; upcoming product launches Zepi and Zeglize will leverage the existing sales force with minimal expansion.
